Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828
German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...
Cancer
Simnova Partners with Orna Therapeutics for In Situ CAR Therapies
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a...
WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies
China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK),...
Antengene Acquires Full Rights to Calithera’s CD73 Inhibitor CB-708
China-based Antengene Corporation Ltd (HKG: 6996) has unveiled a transfer agreement with US-headquartered Calithera Biosciences...
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
Duality Biologics, a developer of novel modality drugs operating in the United States and China,...
EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer
EOC Pharma, a biotech company operating in the US and China, has announced that its...
Zhongchao Partners with Natco Pharma to Distribute Drugs in China
Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
China – based Jiangxi Jemincare Group has announced that it has received approval from the...
BeiGene’s Tislelizumab Receives NMPA Review for First-Line HCC Indication
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that a supplementary Biologic License Application...
Immunohead Biotech Raises RMB 200 Million in Series A+ Financing Round
Immunohead Biotechnology Co., Ltd, a cell therapy developer based in Suzhou, has reportedly raised close...
CStone Pharmaceuticals Achieves Primary Endpoint in GEMSTONE-304 Study for Sugemalimab
China-based CStone Pharmaceuticals (HKG: 2616) has announced the achievement of the primary endpoint in the...
3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
Changzhou Qianhong Completes Phase I Study of QHRD107 for Acute Myeloid Leukemia
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced the completion of enrollment and...
Shuwen Biotech Partners with Nottingham University Hospitals for MammaTyper
China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned...